Abstract for: The Impact of Early Decisions in Antiviral Drug Development on the Broader Health System
This research evaluates antiviral drugs (including small molecule antivirals and monoclonal antibodies) developed for the treatment of Covid-19, by modelling the entire end-to-end health system. The scope of the health system being modelled goes from the earliest stages of drug development right up to patient receipt of treatment, and a follow up on patient outcomes. The model will be built using insights from stakeholders across the entire drug life cycle including developers in pharmaceutical companies and academia, regulatory authorities, health care workers and patients. These stakeholder inputs will be gathered via group model building workshops, interviews and focus groups. The model will be used to determine and evaluate the effectiveness of the antiviral treatment options developed as part of the CARE consortium (Corona Accelerated Research and Development in Europe).